乳腺癌患者20年随访期间药物相关性颌骨坏死发生率:一项基于人群的多中心回顾性研究
该研究在奥地利蒂罗尔州全部九家乳腺中心回顾性纳入2000至2020年间接受抗骨吸收治疗的乳腺癌骨转移患者,共639例。中位随访20年期间,56例(8.8%,95%CI 6.6-11.0)发生药物相关性颌骨坏死(MRONJ);单用地舒单抗组发生率为11.6%,单用双膦酸盐组为2.8%,双膦酸盐后序贯地舒单抗组为16.3%。作者结论认为该发生率高于现有文献报道,且地舒单抗组发生MRONJ显著更早。
要点
- 乳腺癌骨转移患者接受抗骨吸收治疗,MRONJ总发生率为8.8%(95%CI 6.6-11.0)。
- 单用地舒单抗组MRONJ发生率为11.6%,单用双膦酸盐组为2.8%,序贯组为16.3%。
- 地舒单抗组发生MRONJ的时间显著更早:单用地舒单抗4.6年,单用双膦酸盐5.1年,序贯组8.4年。
核心结论
- 乳腺癌骨转移患者中MRONJ发生率较现有文献报道明显更高,尤其是接受地舒单抗治疗的患者;接受地舒单抗治疗的患者发生MRONJ显著更早。
研究设计与样本
- 该研究为回顾性多中心研究,于2000至2020年在奥地利蒂罗尔州全部九家乳腺中心开展。
- 利用癌症登记筛查全蒂罗尔州乳腺癌患者,最终纳入所有接受抗骨吸收治疗的乳腺癌骨转移患者,共639例(初筛8860例)。
- 患者每月接受一次抗骨吸收治疗,未进行降阶梯治疗。
主要发现
- 639例患者中56例(8.8%,95%CI 6.6-11.0)诊断为MRONJ。
- 单用地舒单抗组MRONJ发生率为11.6%(95%CI 8.0-15.3),单用双膦酸盐组为2.8%(95%CI 0.7-4.8),双膦酸盐后序贯地舒单抗组为16.3%(95%CI 8.8-23.9)。
- 治疗开始至发生MRONJ的时间:单用地舒单抗组4.6年,单用双膦酸盐组5.1年,双膦酸盐后序贯地舒单抗组8.4年;接受地舒单抗治疗者发生MRONJ显著更早。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for patients with breast cancer and bone metastases. However, the population-based incidence of MRONJ is not well established. We therefore performed a retrospective multicenter study to assess the incidence for a whole Austrian federal state (Tyrol). MATERIALS AND METHODS: This retrospective multicenter study was conducted between 2000 and 2020 at all nine breast centers across Tyrol, Austria. Using the cancer registry, the total Tyrolean population was screened for all patients with breast cancer. All patients with breast cancer and bone metastases receiving antiresorptive therapy were finally included in the study. RESULTS: From 8,860 patients initially screened, 639 individuals were eligible and included in our study. Patients received antiresorptive therapy once per month without de-escalation of therapy. MRONJ was diagnosed in 56 (8.8%, 95% CI, 6.6 to 11.0) patients. The incidence of MRONJ was 11.6% (95% CI, 8.0 to 15.3) in individuals treated with denosumab only, 2.8% (95% CI, 0.7 to 4.8) in those treated with bisphosphonates only, and 16.3% (95% CI, 8.8 to 23.9) in the group receiving bisphosphonates followed by denosumab. Individuals developed MRONJ significantly earlier when treated with denosumab. Time to MRONJ after treatment initiation was 4.6 years for individuals treated with denosumab only, 5.1 years for individuals treated with bisphosphonates only, and 8.4 years for individuals treated with both consecutively. CONCLUSION: MRONJ incidence in breast cancer patients with bone metastases was found to be considerably higher, especially for patients receiving denosumab, when compared with available data in the literature. Additionally, patients treated with denosumab developed MRONJ significantly earlier.
引用
- Brunner C, Arvandi M, Marth C, et al. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study. J Clin Oncol. 2024. PMID: 39163561. doi:10.1200/JCO.24.00171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。